| New substitution models for rooting phylogenetic trees TA Williams, SE Heaps, S Cherlin, TMW Nye, RJ Boys, TM Embley Philosophical Transactions of the Royal Society B: Biological Sciences 370 …, 2015 | 55 | 2015 |
| Prediction of treatment response in rheumatoid arthritis patients using genome‐wide SNP data S Cherlin, D Plant, JC Taylor, M Colombo, A Spiliopoulou, E Tzanis, ... Genetic epidemiology 42 (8), 754-771, 2018 | 16 | 2018 |
| The effect of nonreversibility on inferring rooted phylogenies S Cherlin, SE Heaps, TMW Nye, RJ Boys, TA Williams, TM Embley Molecular Biology and Evolution 35 (4), 984-1002, 2018 | 11 | 2018 |
| A Genome-wide Association Study Identifies SERPINB10, CRLF3, STX7, LAMP3, IFNG-AS1, and KRT80 As Risk Loci Contributing to Cutaneous Leishmaniasis … LC Castellucci, L Almeida, S Cherlin, M Fakiola, RW Francis, ... Clinical Infectious Diseases 72 (10), e515-e525, 2021 | 9 | 2021 |
| Using penalized regression to predict phenotype from SNP data S Cherlin, RAJ Howey, HJ Cordell BMC proceedings 12 (9), 223-228, 2018 | 9 | 2018 |
| Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response S Cherlin, MJ Lewis, D Plant, N Nair, K Goldmann, E Tzanis, MR Barnes, ... Annals of the rheumatic diseases 79 (11), 1446-1452, 2020 | 4 | 2020 |
| Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a … N Vergis, R Phillips, V Cornelius, A Katsarou, T Youngstein, L Cook, ... Trials 22 (1), 1-4, 2021 | 3 | 2021 |
| Developing and testing high‐efficacy patient subgroups within a clinical trial using risk scores S Cherlin, JMS Wason Statistics in medicine 39 (24), 3285-3298, 2020 | 3 | 2020 |
| Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential MJ Grayling, T Bigirumurame, S Cherlin, L Ouma, H Zheng, JMS Wason BMC rheumatology 5 (1), 1-15, 2021 | 2 | 2021 |
| Generalizing rate heterogeneity across sites in statistical phylogenetics SE Heaps, TMW Nye, RJ Boys, TA Williams, S Cherlin, TM Embley Statistical Modelling 20 (4), 410-436, 2020 | 1 | 2020 |
| Developing a predictive signature for two trial endpoints using the cross-validated risk scores method S Cherlin, J Wason arXiv preprint arXiv:2007.01680, 2020 | 1 | 2020 |
| A genome-wide association study highlights a regulatory role for IFNG-AS1 contributing to cutaneous leishmaniasis in Brazil LC Castellucci, L Almeida, S Cherlin, M Fakiola, E Carvalho, ... bioRxiv, 2020 | 1 | 2020 |
| Detecting responses to treatment with fenofibrate in pedigrees S Cherlin, MH Wang, H Bickeböller, RM Cantor BMC genetics 19 (1), 133-140, 2018 | 1 | 2018 |
| Rooting major cellular radiations using statistical phylogenetics S Cherlin Newcastle University, 2016 | 1 | 2016 |
| Multi-Arm Trial of Inflammatory Signal Inhibitors (MATIS) for Hospitalised Patients with Mild or Moderate COVID-19 Pneumonia: A Structured Summary of a Study Protocol for a … A Charania, N Vergis, R Phillips, V Cornelius, A Katsarou, T Youngstein, ... Blood 138, 4200, 2021 | | 2021 |
| Cross-validated risk scores adaptive enrichment (CADEN) design S Cherlin, J Wason arXiv preprint arXiv:2111.02299, 2021 | | 2021 |
| LETTER Open Access N Vergis, R Phillips, V Cornelius, A Katsarou, T Youngstein, L Cook, ... | | 2021 |
| Developing and testing high-efficacy patient subgroups within a clinical trial using polygenic risk scores S Cherlin, J Wason TRIALS 20, 2019 | | 2019 |
| Prediction of treatment response from genome-wide SNP data in rheumatoid arthritis patients S Cherlin, HJ Cordell GENETIC EPIDEMIOLOGY 42 (7), 692-692, 2018 | | 2018 |
| Predicting Treatment Response in Rheumatoid Arthritis Using SNP Data S Cherlin, HJ Cordell GENETIC EPIDEMIOLOGY 41 (7), 666-666, 2017 | | 2017 |
